

| OMB APPROVAL                                 |           |
|--|-----------|
| OMB Number:                                  | 3235-0287 |
| Estimated average burden hours per response: | 0.5       |

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|   |  |  |
|---|--|--|
| 1. Name and Address of Reporting Person*<br><b>Francois Cedric</b><br><br>(Last) (First) (Middle)<br><b>C/O APELLIS PHARMACEUTICALS, INC</b><br><b>100 FIFTH AVENUE, 3RD FLOOR</b><br><br>(Street)<br><b>WALTHAM MA 02451</b><br><br>(City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol<br><b>Apellis Pharmaceuticals, Inc. [ APLS ]</b> | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br><input checked="" type="checkbox"/> Director 10% Owner<br><input checked="" type="checkbox"/> Officer (give title below) Other (specify below)<br><b>Chief Executive Officer</b> |
|   | 3. Date of Earliest Transaction (Month/Day/Year)<br><b>01/15/2020</b>                        |  |
|   | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                     |  |

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |                         | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-------------------------|---|--|---|
|                                 |                                      |  | Code                           | V | Amount  | (A) or (D) | Price                   |   |  |   |
| Common Stock                    | 01/15/2020                           |  | S                              |   | 26,076  | D          | \$42.159 <sup>(1)</sup> | 1,011,355   | D  |   |
| Common Stock                    | 01/15/2020                           |  | S                              |   | 4,562   | D          | \$42.547 <sup>(2)</sup> | 1,006,793   | D  |   |
| Common Stock                    | 01/15/2020                           |  | S <sup>(3)</sup>               |   | 5,000   | D          | \$41.47                 | 1,001,793   | D  |   |
| Common Stock                    | 01/15/2020                           |  | M <sup>(4)</sup>               |   | 30,638  | A          | \$2.14                  | 1,001,793   | D  |   |
| Common Stock                    |                                      |  |                                |   |   |            |                         | 234,411   | I  | See Footnote <sup>(5)</sup>                           |

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |        | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |       |
|--|--|--------------------------------------|--|--------------------------------|---|--|--------|--|-----------------|---|--|--|---|--|-------|
|  |  |                                      |  | Code                           | V | (A)  | (D)    | Date Exercisable   | Expiration Date |   |  |  |   |  | Title |
| Stock Option (Right to Buy)                | \$2.14   | 01/15/2020                           |  | M <sup>(4)</sup>               |   |  | 30,638 | (6)  | 05/12/2020      | Common Stock  | 30,638                                     | \$0  | 153,185   | D  |       |

**Explanation of Responses:**

- Average Sale Price: Min. \$41.46 Max. \$42.45
- Average Sale Price: Min. \$42.46 Max. \$42.66
- This is a scheduled sale from 10B5-1 trading plan.
- This is a scheduled exercise from 10B5-1 trading plan.
- The securities are held by The Francois-DuBois Educational Trust (the "Trust"), for which Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.
- This option was granted on May 12, 2010 and is fully vested.

/s/ David Watson, attorney-in-fact for Cedric Francois      01/16/2020

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.